The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Open accessAbstract
The tumour suppressor gene, phosphatase and tensin homolog (PTEN), is one of the most commonly mutated genes in human cancers. Recent evidence suggests that PTEN is important for the maintenance of genome stability. Here, we show that PTEN deficiency causes a homologous recombination (HR) defect in human tumour cells. The HR deficiency caused by PTEN deficiency, sensitizes tumour cells to potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), both in vitro and in vivo. PARP inhibitors are now showing considerable promise in the clinic, specifically in patients with mutations in either of the breast cancer susceptibility genes BRCA1 or BRCA2. The data we present here now suggests that the clinical assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citationSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationMaehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Self-citationYang, H., Kong, W., He, L., Zhao, J.-J., O'Donnell, J. D., Wang, J., Wenham, R. M., Coppola, D., Kruk, P. A., Nicosia, S. V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2488 · Cited by 1,051
Tenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Self-citationEssential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
Molecular views of recombination proteins and their control
West, S. C. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1127 · Cited by 956
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Self-citationUbiquitination regulates PTEN nuclear import and tumor suppression
Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.040 · Cited by 748
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network
Song, M. S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, J., & Pandolfi, P. P. (2008) · Nature · doi:10.1038/nature07290 · Cited by 548
The role of PTEN signaling perturbations in cancer and in targeted therapy
Keniry, M., & Parsons, R. (2008) · Oncogene · doi:10.1038/onc.2008.248 · Cited by 358
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P. W. B., Holstege, H., Liu, X., van Drunen, E., Beverloo, H. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4953 · Cited by 335
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Turner, N. C., Lord, C. J., Iorns, E., Brough, R., Swift, S., Elliott, R., Rayter, S., Tutt, A. N., & Ashworth, A. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.61 · Cited by 322
Self-citationUnderstanding PTEN regulation: PIP2, polarity and protein stability
Leslie, N. R., Batty, I. H., Maccario, H., Davidson, L., & Downes, C. P. (2008) · Oncogene · doi:10.1038/onc.2008.243 · Cited by 221
TUTT, A. N. J., LORD, C. J., MCCABE, N., FARMER, H., TURNER, N., MARTIN, N. M., JACKSON, S. P., SMITH, G. C. M., & ASHWORTH, A. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.012 · Cited by 196
Self-citationWhiteman, D. C., Zhou, X., Cummings, M. C., Pavey, S., Hayward, N. K., & Eng, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10294 · Cited by 187
Zhou, X.-P., Loukola, A., Salovaara, R., Nystrom-Lahti, M., Peltomäki, P., de la Chapelle, A., Aaltonen, L. A., & Eng, C. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64200-9 · Cited by 185
Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA
Kim, J.-S., Lee, C., Bonifant, C. L., Ressom, H., & Waldman, T. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00537-06 · Cited by 161
Self-citationMethylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma
Wiencke, J. K., Zheng, S., Jelluma, N., Tihan, T., Vandenberg, S., Tamgüney, T., Baumber, R., Parsons, R., Lamborn, K. R., Berger, M. S., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-003 · Cited by 161
Chemically targeting the PI3K family
Knight, Z. A., & Shokat, K. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350245 · Cited by 134
Gupta, A. K. D., Yang, Q., PANDITA, R. K., Hunt, C. R., Tao, X., Misri, S., Zeng, S., Pagan, J. K., Jeffery, J., Puc, J., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.14.8947 · Cited by 123
Tachibana, M., Shibakita, M., Ohno, S., Kinugasa, S., Yoshimura, H., Ueda, S., Fujii, T., Rahman, M. A., Dhar, D. K., & Nagasue, N. (2002) · Cancer · doi:10.1002/cncr.0678 · Cited by 104
Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions
Saeki, H., Siaud, N., Christ, N., Wiegant, W. W., van Buul, P. P. W., Han, M., Zdzienicka, M. Z., Stark, J. M., & Jasin, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600298103 · Cited by 99
Activated PI3K Signaling as an Endogenous Inducer of p53 in Human Cancer
Lee, C. S., Kim, J.-S., & Waldman, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.4.3810 · Cited by 25
Self-citation
Cited by
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
Self-citation
Metadata
- Authors
- Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T., Lord, C. J., & Ashworth, A.
- Venue
- EMBO Molecular Medicine
- Published
- 2009-09
- Volume
- 1
- Issue
- 6-7
- Pages
- 315-322
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2116005493
- Cited by
- 638
- References
- 28
- FWCI
- 26.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.